Nasdaq

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...
Nasdaq

Capricor Therapeutics Submits BLA for Deramiocel, Potentially First Therapy for DMD Cardiomyopathy, Triggering $10 Million Milestone Payment from Nippon Shinyaku

Capricor Therapeutics has submitted a Biologics License Application (BLA) to the FDA for deramiocel, an investigational cell therapy intended to treat Duchenne muscular dystrophy (DMD) cardiomyopathy, ...
Seeking Alpha

Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy

SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (CAPR) (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of ...